Evidence map›Paper›PMID 29713762›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2018

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with

Leszek Krolicki, Frank Bruchertseifer, Jolanta Kunikowska, Henryk Koziara, Bartosz Królicki, Maciej Jakuciński, Dariusz Pawlak, Christos Apostolidis, Saed Mirzadeh, Rafał Rola and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Prospective phase II trial of [EJNMMI research · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Leszek KrolickiDepartment of Nuclear Medicine, Medical University of Warsaw, ul. Banacha 1 a, 02-097, Warsaw, Poland.
Frank BruchertseiferEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Jolanta KunikowskaDepartment of Nuclear Medicine, Medical University of Warsaw, ul. Banacha 1 a, 02-097, Warsaw, Poland. jolanta.kunikowska@wum.edu.p.
Henryk KoziaraDepartment of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland.
Bartosz KrólickiDepartment of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland.
Maciej JakucińskiDepartment of Nuclear Medicine, Brodnowski Hospital, Warsaw, Poland.
Dariusz PawlakRadioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.
Christos ApostolidisEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Saed MirzadehNuclear and Radiochemistry Group, Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, 38731-6229, USA.
Rafał RolaDepartment of Neurology, Military Institute of Aviation Medicine, Warsaw, Poland.
Adrian MerloNeurosurgery, Bern and University of Basel, Spitalgasse 32, Bern, Switzerland.
Alfred MorgensternEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Joint Research Centre · DEInstitute of Psychiatry and Neurology · PLMedical University of Warsaw · PLNational Centre for Nuclear Research · PLOak Ridge National Laboratory · USUniversity of Basel · CHWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha emitters, e.g. MATERIAL AND

methodsAmong 50 glioma patients of different subtypes that have to date been treated with targeted alpha therapy at the Medical University Warsaw, we report here the data on nine patients with secondary GBM. Following surgery, chemo- and radiotherapy, recurrent GBM was treated by intracavitary injection of 1-6 doses of 0.9-2.3 GBq

resultsTreatment with activities ranging from 1.4 to 9.7 (median 5.8) GBq

conclusionsTargeted alpha therapy of secondary GBM with

Indexed as

AdultBismuthBrain NeoplasmsFemaleGlioblastomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalOrganometallic CompoundsPositron Emission Tomography Computed TomographyRadioisotopesSubstance PSurvival AnalysisTissue DistributionYoung AdultBismuthBismuth-213Organometallic CompoundsRadioisotopesSubstance Psubstance P, 213Bi-DOTA(thienylalanyl(8)-methionyl(O2)(11))-213Bi-DOTA-SP68Ga-DOTA-SPGBMGlioblastomaSubstance PTargeted alpha therapy

Identifiers

PMID29713762
PMCPMC6061489
OpenAlexW2800794850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.